Robitaille will focus on bringing new products to market, generating revenue and increasing brand awareness alongside the company’s seasoned senior management team
WOODINVILLE, Wash., June 7, 2022 /PRNewswire/ — Anavasi Diagnostics (“Anavasi”), a medical technology company focused on the development of novel molecular diagnostic tests, announced the addition of Scott Robitaille as Vice President of Sales and Marketing.
Robitaille comes to Anavasi with deep knowledge of the medical device and molecular diagnostics industry and over two decades of experience in sales, marketing and channel management. During his career with companies such as Immunostics, Chembio Diagnostics and Abbott’s Alere Inc., Scott has a proven track record of initiating and leading change, delivering results and transforming businesses to improve the customer experience. In his recent role at Visby Medical, Scott led contract negotiations, developing profitable long-term customer accounts through relationships with key distribution channel partners.
“I am honored to join Anavasi at this crucial stage in the company’s growth,” said Scott. “With our innovative and disruptive technology, I look forward to solidifying Anavasi’s place in the medical diagnostics market as an industry leader,” said Robitaille.
“We are thrilled to have Scott join our team,” said Nelson Patterson, President and CEO of Anavasi Diagnostics. “We looked for a leader with proven product launch results, who built strong teams, and who was a proven leader in diagnostics. Scott met all of these criteria, and we are happy to have him on our team. sides. He will be an essential part of our success.”
Robitaille joins Anavasi Diagnostics’ leadership team of highly regarded industry leaders, including Patterson (President and CEO), Scott Hales (Financial director), Michael BlaivasMD, FACEP (Chief Medical Officer) and Guy Ellis (CEO). Anavasi’s three co-founders also remain actively involved in day-to-day operations and development: Barry LutzPhD (scientific director), Robert Atkinson (Head of Innovation and Technology) and Minh Duong (Head of Engineering). Anavasi is a portfolio company in the National Institutes of Health’s Rapid Acquisition of Diagnostics (RADx) program, where it received $14.9M in funding contracts for rapid scale-up and commercialization of its AsecencioDx™ platform. The Company has also raised $8.6M to date under separate funding and is currently completing a $6 million round bridge and the kick off of a $20 million Series A Increase.
“Anavasi continues to increase productivity by focusing on market readiness as we await final FDA Emergency Use Clearance (EUA) for the Ascencio platform. We are excited about the expertise in sales, marketing and business development that Scott will bring to our team. These areas will be critical to the business as we begin to deploy the AscencioDx™ platform in healthcare facilities and work on future product developments.” said Patterson.
For more information, please visit www.anavasidx.com.
About Anavasi Diagnostics
Anavasi Diagnostics is a medical technology company focused on saving lives by developing novel molecular diagnostic tests using proprietary, patent-pending reverse transcriptase methodology. It was founded by world-renowned academic researchers, senior medical device and clinical diagnostics engineering and design executives, manufacturing experts, and a former Microsoft software veteran. Throughout their career, the team has been responsible for the introduction of over forty medical/diagnostic products and over 350 peer-reviewed research publications. www.anavasidx.com